Saudi Arabia Turkey And Egypt In Vitro Diagnostics Ivd Quality Control Market
Tamaño del mercado en miles de millones de dólares
Tasa de crecimiento anual compuesta (CAGR) : %
Período de pronóstico |
2023 –2030 |
Tamaño del mercado (año base) |
USD 867.09 Thousand |
Tamaño del mercado (año de pronóstico) |
USD 1,260.66 Thousand |
Tasa de crecimiento anual compuesta (CAGR) |
|
Jugadoras de los principales mercados |
Saudi Arabia, Turkey, and Egypt In Vitro Diagnostics (IVD) Quality Control Market, By Product and Services (Quality Control Products and Quality Control Services), Application (Clinical Chemistry, Immunochemistry, Hematology, Molecular Diagnostics, Coagulation/Hemostasis, Microbiology, and Others), Sector (Clinical and Non-Clinical), End User (Clinical Laboratories, Academic and Research Institutes, Blood Banks, Biotechnology Industry, Pharmaceutical Industry, and Others)-Industry Trends and Forecast to 2030.
Saudi Arabia, Turkey, and Egypt in Vitro Diagnostics (IVD) Quality Control Market Analysis and Size
The rising prevalence of chronic diseases across Saudi Arabia, Turkey, and Egypt has enhanced the market demand. The rising healthcare expenditure for better health services also contributes to the market's growth. The major market players focus on various product launches and approvals during this crucial period. In addition, the increase in improved quality control services also contributes to the rising demand for the IVD quality control market.
Saudi Arabia, Turkey, and Egypt In vitro diagnostics (IVD) quality control market is expected to gain market growth in the forecast period of 2023 to 2030. Data Bridge Market Research analyses that the market is growing with a CAGR of 4.8% in the forecast period of 2023 to 2030 and is expected to reach USD 1,260.66 thousand by 2030 from USD 867.09 thousand in 2022.
Report Metric |
Details |
Forecast Period |
2023 to 2030 |
Base Year |
2022 |
Historic Years |
2021 (Customizable to 2015-2020) |
Quantitative Units |
Revenue in USD Thousand |
Segments Covered |
Product and Services (Quality Control Products and Quality Control Services), Application (Clinical Chemistry, Immunochemistry, Hematology, Molecular Diagnostics, Coagulation/Hemostasis, Microbiology, and Others), Sector (Clinical and Non-Clinical), End User (Clinical Laboratories, Academic and Research Institutes, Blood Banks, Biotechnology Industry, Pharmaceutical Industry, and Others) |
Countries Covered |
Saudi Arabia, Turkey, and Egypt |
Market Players Covered |
The major companies which are dealing in the market are Bio-Rad Laboratories, Inc, Siemens Healthcare Private Limited, Sysmex Europe SE, Randox Laboratories Ltd., Sera Care, Thermo Fisher Scientific Inc., Beckman Coulter, Inc., Technopath Clinical Diagnostics, DiaSorin S.p.A., Agappe Diagnostics Ltd, and Spectrum Diagnostics. among others |
Market Definition
In vitro diagnostic products are those reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including a determination of the state of health, in order to cure, mitigate, treat, or prevent disease or its sequelae. Such products are intended for use in the collection, preparation, and examination of specimens taken from the human body.
IVD quality controls are samples/materials used to validate the reliability of the IVD testing system to ensure the accuracy of test results and evaluate the impact of factors such as environmental conditions and operator’s performance on test results. Moreover, they can also be used to monitor a patient’s health, cure diseases, and also enable medical professionals to identify the most effective treatment procedure or therapy for the patient.
In Vitro Diagnostics (IVD) Quality Control Market Dynamics
This section deals with understanding the market drivers, opportunities, restraints and challenges. All of this is discussed in detail as below:
Drivers
- Rising Prevalence of Chronic Diseases Across Saudi Arabia, Turkey, and Egypt
Chronic diseases and conditions are on the rise globally. An aging population and a sedentary lifestyle are contributing to a steady increase in long-term health problems. An increasing prevalence of chronic and infectious diseases has led to the launch of rapid diagnostic and testing tools by leading market players. Besides, the rising adoption of self-test and point-of-care devices is further accelerating the growth of in-vitro diagnostics devices across the globe
Thus, the increasing number of chronic disease are expected to accelerate the growth of the IVD quality control market significantly in the nearby future.
- Rising Adoption of Quality Control Solutions in Laboratories and Hospitals
Laboratory testing of patient samples can be a complex procedure, depending on clinical analysis, microbiological study, or blood banking testing among other facets of the clinical laboratory. Quality control (QC) is one of the most important impacts on laboratory testing-it ensures both the precision and accuracy of patient sample results. The integrity of quality control samples is important to both management of overall quality as well as to meeting requirements of proficiency testing.
Thus, the rising adoption of quality control solutions in laboratories and hospitals is expected to drive the market growth.
Opportunities
-
Rise in Strategic Acquisition and Partnership among Organizations
Recently, different organizations are stepping forward for partnership and collaboration to develop IVDs that are essential for detecting diseases. Not only can this, with the help of partnerships and agreements, both the companies develop a new suite of technologies and platforms that will help to detect diseases.
With the help of a long-term agreement, both companies can provide dimensional pricing IVDs in response to consumer demand in the market. Such partnership and mutual agreement not only benefit both the companies but are also creating a lot of opportunities for the market to grow.
-
Rising Research and Development Activities
Across the globe, the spending on research and development activities is escalating owing to public health expenditure with economic performance. Whereas, the healthcare industry ranks second among all industries when it comes to the amount it spends on research and development. Rising healthcare expenditure has further resulted in better provision of research and development opportunities. Consequently, it has enhanced the demand for IVD regulatory affairs outsourcing services across the region.
Restraints/Challenges
- High Cost Related to Quality Control and Maintenance of IVD
In vitro diagnostics (IVD) are tests done on samples such as blood or tissue that have been taken from the human body. In vitro diagnostics can detect diseases or other conditions, and can be used to monitor a person's overall health to help cure, treat, or prevent diseases.
IVD of analytes originating from body specimens, including blood and tissue biopsies, is used alone or in combination with clinical investigations and is perceived as an important tool for high-quality medical outcomes, hence maintaining of IVD and quality control of IVD devices costs high for carrying out accurate tests.
Hence, the rising cost of the maintenance of IVD has become a deciding factor for the companies in the servicing process, which is further restraining the growth of the market to an extent.
- Stringent Regulations Regarding IVD in Saudi Arabia, Turkey, and Egypt
The use of IVDs across the globe is rapidly increasing, with the growth of the aged population and several chronic diseases which are preventable by early diagnosis and timely treatments. At the same time, the players of the IVD devices in the market have to follow certain regulations to get approval from the upper authorities for the launching of the product in a region. These stringent guidelines need to be followed, and this is one of the most difficult tasks among all the steps. The pre-market approval of various medical devices varies from one country to another.
Therefore, the stringent rules & regulations for product approval act as restraints for the growth of the market.
Recent Development
- In February 2023, Siemens Healthineers, a leading medical technology company, and Unilabs, a leading diagnostic services provider, announced a multi-year agreement valued at over €200 thousand. Unilabs has invested in Siemens Healthineers top-notch technology and will acquire more than 400 laboratory analyzers to further improve its laboratory infrastructure to offer an unparalleled service to its customers. This partnership has helped for latest diagnostic testing infrastructure to improve patients’ care.
- In July 2021, Thermo Fisher Scientific, the world leader in serving science, announced a collaboration with Ortho Clinical Diagnostics to promote and distribute Thermo Scientific MAS Quality Controls and LabLink xL Quality Assurance Software for use with Ortho Clinical Diagnostics VITROS analyzers. This has helped the company to increase their global presence in the market.
Saudi Arabia, Turkey, and Egypt in Vitro Diagnostics (IVD) Quality Control Market Scope
Saudi Arabia, Turkey, and Egypt in vitro diagnostics (IVD) quality control market is segmented into four notable segments such as product and services, application, type, sector and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Product and Services
- Quality Control Products
- Quality Control Services
On the basis of products and services, the Saudi Arabia, Turkey, and Egypt In vitro diagnostics (IVD) quality control market is segmented into quality control products and quality control services.
Applications
- Clinical Chemistry
- Immunochemistry
- Hematology
- Molecular Diagnostics
- Coagulation/Hemostasis
- Microbiology
- Others
Based on applications, the Saudi Arabia, Turkey, and Egypt In vitro diagnostics (IVD) quality control market is segmented into clinical chemistry, immunochemistry, hematology, molecular diagnostics, coagulation/hemostasis, microbiology, and others.
Sector
- Clinical
- Non-Clinical
Based on sector, the Saudi Arabia, Turkey, and Egypt In vitro diagnostics (IVD) quality control market is segmented into clinical and non-clinical.
End User
- Clinical Laboratories
- Academic And Research Institutes
- Blood Banks
- Biotechnology Industry
- Pharmaceutical Industry
- Others
Based on end users, the Saudi Arabia, Turkey, and Egypt In vitro diagnostics (IVD) quality control market is segmented into clinical laboratories, academic and research institutes, blood banks, biotechnology industry, pharmaceutical industry, and others.
Competitive Landscape and In Vitro Diagnostics (IVD) Quality Control Market Share Analysis
The in vitro diagnostics (IVD) quality control market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on the ataxia market.
Some of the major players operating in the In vitro diagnostics (IVD) quality control market are Bio-Rad Laboratories, Inc, Siemens Healthcare Private Limited, Sysmex Europe SE, Randox Laboratories Ltd., Sera Care, Thermo Fisher Scientific Inc., Beckman Coulter, Inc., Technopath Clinical Diagnostics, DiaSorin S.p.A., Agappe Diagnostics Ltd, and Spectrum Diagnostics. among others.
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF SAUDI ARABIA, TURKEY, AND EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 SAUDI ARABIA PRODUCTS AND SERVICES, LIFELINE CURVE
2.8 EGYPT PRODUCTS AND SERVICES, LIFELINE CURVE
2.9 TURKEY PRODUCTS AND SERVICES, LIFELINE CURVE
2.1 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.11 DBMR MARKET POSITION GRID
2.12 MARKET TESTING TYPE COVERAGE GRID
2.13 VENDOR SHARE ANALYSIS
2.14 SECONDARY SOURCES
2.15 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL'S MODEL
4.2 PORTER'S 5 FORCES
4.3 INDUSTRY INSIGHTS
5 REGULATORY GUIDELINES FOR IN VITRO DIAGNOSTICS QUALITY CONTROL
5.1 REGULATIONS IN SAUDI ARABIA
5.2 REGULATIONS IN TURKEY
5.3 REGULATIONS IN EGYPT
5.3.1 MEDICAL DEVICE REGISTRATION IN EGYPT, THE PROCESS IN BRIEF:
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF CHRONIC DISEASES ACROSS SAUDI ARABIA, TURKEY, AND EGYPT
6.1.2 RISING ADOPTION OF QUALITY CONTROL SOLUTIONS IN LABORATORIES AND HOSPITALS
6.1.3 ADVANCEMENTS IN TECHNOLOGY LEADING TO THE DEVELOPMENT OF NEW AND ADVANCED DIAGNOSTIC PRODUCTS
6.1.4 RISING USE OF QUALITY CONTROL IN MOLECULAR DIAGNOSTICS
6.2 RESTRAINTS
6.2.1 HIGH COST RELATED TO QUALITY CONTROL AND MAINTENANCE OF IVD
6.2.2 STRINGENT REGULATIONS REGARDING IVD IN SAUDI ARABIA, TURKEY, AND EGYPT
6.3 OPPORTUNITIES
6.3.1 RISE IN STRATEGIC ACQUISITION AND PARTNERSHIP AMONG ORGANIZATIONS
6.3.2 RISING RESEARCH AND DEVELOPMENT ACTIVITIES
6.4 CHALLENGES
6.4.1 LACK OF INFRASTRUCTURE IN HEALTHCARE SERVICE
6.4.2 SHORTAGE OF SKILLED PERSONNEL FOR HANDLING QUALITY CONTROL OF IN VITRO DIAGNOSTIC DEVICES.
7 SAUDI ARABIA, TURKEY, AND EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY PRODUCT AND SERVICES
7.1 OVERVIEW
7.2 QUALITY CONTROL PRODUCTS
7.2.1 SERUM/PLASMA-BASED CONTROL
7.2.2 WHOLE BLOOD-BASED CONTROLS
7.2.3 URINE-BASED CONTROLS
7.2.4 OTHER CONTROLS
7.2.5 INTERNAL QUALITY CONTROL
7.2.6 EXTERNAL QUALITY CONTROL
7.3 QUALITY CONTROL SERVICES
8 SAUDI ARABIA, TURKEY, AND EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 CLINICAL CHEMISTRY
8.3 IMMUNOCHEMISTRY
8.4 HEMATOLOGY
8.5 MOLECULAR DIAGNOSTICS
8.5.1 QUALITY CONTROL PRODUCTS
8.5.1.1 INTERNAL QUALITY CONTROL
8.5.1.2 EXTERNAL QUALITY CONTROL
8.5.2 QUALITY CONTROL SERVICES
8.6 COAGULATION/HEMOSTASIS
8.7 MICROBIOLOGY
8.8 OTHERS
9 SAUDI ARABIA, TURKEY, AND EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY SECTOR
9.1 OVERVIEW
9.2 CLINICAL
9.3 NON-CLINICAL
10 SAUDI ARABIA, TURKEY, AND EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY END USER
10.1 OVERVIEW
10.2 CLINICAL LABORATORIES
10.3 ACADEMIC AND RESEARCH INSTITUTES
10.4 PHARMACEUTICAL INDUSTRY
10.5 BIOTECHNOLOGY INDUSTRY
10.6 BLOOD BANKS
10.7 OTHERS
11 SAUDI ARABIA, TURKEY, AND EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, COMPANY LANDSCAPE
11.1 COMPANY SHARE ANALYSIS: SAUDI ARABIA
11.2 COMPANY SHARE ANALYSIS: EGYPT
11.3 COMPANY SHARE ANALYSIS: TURKEY
12 SWOT ANALYSIS
13 TURKEY IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, COMPANY PROFILES
13.1 THERMO FISHER SCIENTIFIC INC.
13.1.1 COMPANY SNAPSHOT
13.1.2 REVENUE ANALYSIS
13.1.3 PRODUCT PORTFOLIO
13.1.4 RECENT DEVELOPMENTS
13.2 SIEMENS HEALTHCARE GMBH
13.2.1 COMPANY SNAPSHOT
13.2.2 REVENUE ANALYSIS
13.2.3 PRODUCT PORTFOLIO
13.2.4 RECENT DEVELOPMENT
13.3 BIO-RAD LABORATORIES, INC.
13.3.1 COMPANY SNAPSHOT
13.3.2 REVENUE ANALYSIS
13.3.3 PRODUCT PORTFOLIO
13.3.4 RECENT DEVELOPMENT
13.4 BECKMAN COULTER, INC.
13.4.1 COMPANY SNAPSHOT
13.4.2 PRODUCT PORTFOLIO
13.4.3 RECENT DEVELOPMENT
13.5 SYSMEX CORPORATION
13.5.1 COMPANY SNAPSHOT
13.5.2 REVENUE ANALYSIS
13.5.3 PRODUCT PORTFOLIO
13.5.4 RECENT DEVELOPMENT
13.6 AGAPPE DIAGNOSTICS LTD
13.6.1 COMPANY SNAPSHOT
13.6.2 PRODUCT PORTFOLIO
13.6.3 RECENT DEVELOPMENT
13.7 DIASORIN MOLECULAR LLC.
13.7.1 COMPANY SNAPSHOT
13.7.2 PRODUCT PORTFOLIO
13.7.3 RECENT DEVELOPMENT
13.8 RANDOX LABORATORIES LTD.
13.8.1 COMPANY SNAPSHOT
13.8.2 PRODUCT PORTFOLIO
13.8.3 RECENT DEVELOPMENT
13.9 SERA CARE
13.9.1 COMPANY SNAPSHOT
13.9.2 PRODUCT PORTFOLIO
13.9.3 RECENT DEVELOPMENT
13.1 SPECTRUM DIAGNOSTICS
13.10.1 COMPANY SNAPSHOT
13.10.2 PRODUCT PORTFOLIO
13.10.3 RECENT DEVELOPMENT
13.11 TECHNOPATH CLINICAL DIAGNOSTICS
13.11.1 COMPANY SNAPSHOT
13.11.2 PRODUCT PORTFOLIO
13.11.3 RECENT DEVELOPMENT
14 QUESTIONNAIRE
15 RELATED REPORTS
Lista de figuras
FIGURE 1 SAUDI ARABIA, TURKEY, AND EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET: SEGMENTATION
FIGURE 2 SAUDI ARABIA, TURKEY, AND EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET: DATA TRIANGULATION
FIGURE 3 SAUDI ARABIA, TURKEY, AND EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET: DROC ANALYSIS
FIGURE 4 SAUDI ARABIA IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET: COUNTRY MARKET ANALYSIS
FIGURE 5 EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET: COUNTRY MARKET ANALYSIS
FIGURE 6 TURKEYS IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET: COUNTRY MARKET ANALYSIS
FIGURE 7 SAUDI ARABIA, TURKEY, AND EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 8 SAUDI ARABIA, TURKEY, AND EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 9 SAUDI ARABIA, TURKEY, AND EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET: DBMR MARKET POSITION GRID
FIGURE 10 SAUDI ARABIA, TURKEY, AND EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET: MARKET TESTING TYPE COVERAGE GRID
FIGURE 11 SAUDI ARABIA, TURKEY, AND EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET: VENDOR SHARE ANALYSIS
FIGURE 12 SAUDI ARABIA, TURKEY, AND EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET: SEGMENTATION
FIGURE 13 RISING PREVALENCE OF CHRONIC DISEASES ACROSS SAUDI ARABIA IS EXPECTED TO DRIVE THE SAUDI ARABIA IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET IN THE FORECAST PERIOD
FIGURE 14 RISING ADOPTION OF QUALITY CONTROL SOLUTIONS IN LABORATORIES AND HOSPITALS IS EXPECTED TO DRIVE THE TURKEY IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET IN THE FORECAST PERIOD IN THE FORECAST PERIOD
FIGURE 15 ADVANCEMENTS IN TECHNOLOGY LEADING TO THE DEVELOPMENT OF NEW AND ADVANCED DIAGNOSTIC PRODUCTS ARE EXPECTED TO DRIVE THE EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET IN THE FORECAST PERIOD IN THE FORECAST PERIOD
FIGURE 16 THE PRODUCT AND SERVICES TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE SAUDI ARABIA IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET IN 2023 & 2030
FIGURE 17 THE PRODUCT AND SERVICES TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE TURKEY IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET IN 2023 & 2030
FIGURE 18 THE PRODUCT AND SERVICES TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET IN 2023 & 2030
FIGURE 19 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF SAUDI ARABIA, TURKEY, AND EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET
FIGURE 20 SAUDI ARABIA, IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY PRODUCTS AND SERVICES, 2022
FIGURE 21 TURKEY, IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY PRODUCTS AND SERVICES, 2022
FIGURE 22 EGYPT, IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY PRODUCTS AND SERVICES, 2022
FIGURE 23 SAUDI ARABIA IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY PRODUCTS AND SERVICES, 2023-2030 (USD THOUSAND)
FIGURE 24 TURKEY IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY PRODUCTS AND SERVICES, 2023-2030 (USD THOUSAND)
FIGURE 25 EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY PRODUCTS AND SERVICES, 2023-2030 (USD THOUSAND)
FIGURE 26 SAUDI ARABIA IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY PRODUCTS AND SERVICES, CAGR (2023-2030)
FIGURE 27 TURKEY IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY PRODUCTS AND SERVICES, CAGR (2023-2030)
FIGURE 28 EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY PRODUCTS AND SERVICES, CAGR (2023-2030)
FIGURE 29 SAUDI ARABIA, TURKEY AND EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY PRODUCTS AND SERVICES, LIFELINE CURVE
FIGURE 30 TURKEY IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY PRODUCTS AND SERVICES, LIFELINE CURVE
FIGURE 31 EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY PRODUCTS AND SERVICES, LIFELINE CURVE
FIGURE 32 SAUDI ARABIA IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY APPLICATION, 2022
FIGURE 33 TURKEY IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY APPLICATION, 2022
FIGURE 34 EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY APPLICATION, 2022
FIGURE 35 SAUDI ARABIA IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY APPLICATION, 2023-2030 (USD THOUSAND)
FIGURE 36 TURKEY IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY APPLICATION, 2023-2030 (USD THOUSAND)
FIGURE 37 EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY APPLICATION, 2023-2030 (USD THOUSAND)
FIGURE 38 SAUDI ARABIA, IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY APPLICATION, CAGR (2023-2030)
FIGURE 39 TURKEY, IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY APPLICATION, CAGR (2023-2030)
FIGURE 40 EGYPT, IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY APPLICATION, CAGR (2023-2030)
FIGURE 41 SAUDI ARABIA, IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY APPLICATION, LIFELINE CURVE
FIGURE 42 TURKEY, IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY APPLICATION, LIFELINE CURVE
FIGURE 43 EGYPT, IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY APPLICATION, LIFELINE CURVE
FIGURE 44 SAUDI ARABIA, IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY SECTOR, 2022
FIGURE 45 TURKEY, IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY SECTOR, 2022
FIGURE 46 EGYPT, IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY SECTOR, 2022
FIGURE 47 SAUDI ARABIA, IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY SECTOR, 2023-2030 (USD THOUSAND)
FIGURE 48 TURKEY, IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY SECTOR, 2023-2030 (USD THOUSAND)
FIGURE 49 EGYPT, IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY SECTOR, 2023-2030 (USD THOUSAND)
FIGURE 50 SAUDI ARABIA IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY SECTOR, CAGR (2023-2030)
FIGURE 51 TURKEY IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY SECTOR, CAGR (2023-2030)
FIGURE 52 EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY SECTOR, CAGR (2023-2030)
FIGURE 53 SAUDI ARABIA, IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY SECTOR, LIFELINE CURVE
FIGURE 54 TURKEY IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY SECTOR, LIFELINE CURVE
FIGURE 55 EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY SECTOR, LIFELINE CURVE
FIGURE 56 SAUDI ARABIA, IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY END USER, 2022
FIGURE 57 TURKEY IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY END USER, 2022
FIGURE 58 EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY END USER, 2022
FIGURE 59 SAUDI ARABIA, IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY END USER, 2023-2030 (USD THOUSAND)
FIGURE 60 TURKEY, IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY END USER, 2023-2030 (USD THOUSAND)
FIGURE 61 EGYPT, IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY END USER, 2023-2030 (USD THOUSAND)
FIGURE 62 SAUDI ARABIA IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY END USER, CAGR (2023-2030)
FIGURE 63 TURKEY IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY END USER, CAGR (2023-2030)
FIGURE 64 EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY END USER, CAGR (2023-2030)
FIGURE 65 SAUDI ARABIA, IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY END USER, LIFELINE CURVE
FIGURE 66 TURKEY, IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY END USER, LIFELINE CURVE
FIGURE 67 EGYPT, IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET, BY END USER, LIFELINE CURVE
FIGURE 68 SAUDI ARABIA IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET: COMPANY SHARE 2022 (%)
FIGURE 69 EGYPT IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET: COMPANY SHARE 2022 (%)
FIGURE 70 TURKEY IN VITRO DIAGNOSTICS (IVD) QUALITY CONTROL MARKET: COMPANY SHARE 2022 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.